Last reviewed · How we verify
Botulinum toxin A 50u
Botulinum toxin A blocks acetylcholine release at the neuromuscular junction by cleaving SNARE proteins, causing temporary muscle paralysis.
Botulinum toxin A blocks acetylcholine release at the neuromuscular junction by cleaving SNARE proteins, causing temporary muscle paralysis. Used for Cervical dystonia, Blepharospasm, Strabismus.
At a glance
| Generic name | Botulinum toxin A 50u |
|---|---|
| Also known as | BOTOX®, OnabotulinumtoxinA |
| Sponsor | EvergreenHealth |
| Drug class | Neurotoxin; Acetylcholine release inhibitor |
| Target | SNAP-25 (synaptosome-associated protein of 25 kDa) |
| Modality | Small molecule |
| Therapeutic area | Neurology; Dermatology; Aesthetics |
| Phase | FDA-approved |
Mechanism of action
Botulinum toxin A is a neurotoxin that irreversibly cleaves SNARE proteins (specifically SNAP-25) required for acetylcholine vesicle fusion and release at the presynaptic terminal. This prevents neuromuscular transmission and results in flaccid paralysis of the targeted muscle. The effect is temporary, lasting 3-4 months, after which nerve terminals regenerate and muscle function returns.
Approved indications
- Cervical dystonia
- Blepharospasm
- Strabismus
- Chronic migraine
- Hyperhidrosis
- Facial wrinkles and dynamic expression lines (cosmetic)
Common side effects
- Headache
- Neck pain
- Injection site pain or bruising
- Muscle weakness (localized)
- Ptosis (eyelid drooping)
- Diplopia (double vision)
Key clinical trials
- Intraoral Administration of Botox in Patients With Dentoalveolar Neuropathic Pain (PHASE2)
- Safety and Efficacy of Botulinum Toxin A in Patients With Posttraumatic Headache (PHASE3)
- The Use of Botulinum Toxin in the Management of Myofascial Pain Syndrome (PHASE1, PHASE2)
- Botox in the Healing of Surgical Wounds of the Neck (PHASE2)
- Safety and Efficacy of CKDB-501B in Subjects With Moderate-to-severe Glabellar Lines (PHASE1)
- A Pilot Study of the Effects of Botulinum Toxin in the Treatment of Provoked Vestibulodynia (PHASE3)
- Onabotulinumtoxin A and Hyaluronic Acid Fillers in the Treatment of Facial Paralysis (PHASE2)
- Botulinum Toxin A for the Treatment of Chemotherapy Induced Peripheral Neuropathy (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Botulinum toxin A 50u CI brief — competitive landscape report
- Botulinum toxin A 50u updates RSS · CI watch RSS
- EvergreenHealth portfolio CI